Literature DB >> 22952058

CSE1L, a novel microvesicle membrane protein, mediates Ras-triggered microvesicle generation and metastasis of tumor cells.

Ching-Fong Liao1, Shu-Hui Lin, Hung-Chang Chen, Cheng-Jeng Tai, Chun-Chao Chang, Li-Tzu Li, Chung-Min Yeh, Kun-Tu Yeh, Ying-Chun Chen, Tsu-Han Hsu, Shing-Chuan Shen, Woan-Ruoh Lee, Jeng-Fong Chiou, Shue-Fen Luo, Ming-Chung Jiang.   

Abstract

Tumor-derived microvesicles are rich in metastasis-related proteases and play a role in the interactions between tumor cells and tumor microenvironment in tumor metastasis. Because shed microvesicles may remain in the extracellular environment around tumor cells, the microvesicle membrane protein may be the potential target for cancer therapy. Here we report that chromosome segregation 1-like (CSE1L) protein is a microvesicle membrane protein and is a potential target for cancer therapy. v-H-Ras expression induced extracellular signal-regulated kinase (ERK)-dependent CSE1L phosphorylation and microvesicle biogenesis in various cancer cells. CSE1L overexpression also triggered microvesicle generation, and CSE1L knockdown diminished v-H-Ras-induced microvesicle generation, matrix metalloproteinase (MMP)-2 and MMP-9 secretion and metastasis of B16F10 melanoma cells. CSE1L was preferentially accumulated in microvesicles and was located in the microvesicle membrane. Furthermore, anti-CSE1L antibody-conjugated quantum dots could target tumors in animal models. Our findings highlight a novel role of Ras-ERK signaling in tumor progression and suggest that CSE1L may be involved in the "early" and "late" metastasis of tumor cells in tumorigenesis. Furthermore, the novel microvesicle membrane protein, CSE1L, may have clinical utility in cancer diagnosis and targeted cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22952058      PMCID: PMC3521793          DOI: 10.2119/molmed.2012.00205

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  54 in total

1.  Oxidized low-density lipoprotein-dependent platelet-derived microvesicles trigger procoagulant effects and amplify oxidative stress.

Authors:  Hua Wang; Zhi-Hao Wang; Jing Kong; Meng-Yun Yang; Gui-Hua Jiang; Xu-Ping Wang; Ming Zhong; Yun Zhang; Jing-Ti Deng; Wei Zhang
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

2.  Export of importin alpha from the nucleus is mediated by a specific nuclear transport factor.

Authors:  U Kutay; F R Bischoff; S Kostka; R Kraft; D Görlich
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

3.  The prognostic significance of nuclear CSE1L in urinary bladder urothelial carcinomas.

Authors:  Chun-Chao Chang; Cheng-Jeng Tai; Tzu-Cheng Su; Ko-Hung Shen; Shu-Hui Lin; Chung-Min Yeh; Kun-Tu Yeh; Yueh-Min Lin; Ming-Chung Jiang
Journal:  Ann Diagn Pathol       Date:  2012-04-02       Impact factor: 2.090

4.  Expression of the proliferation and apoptosis-associated CAS protein in benign and malignant cutaneous melanocytic lesions.

Authors:  R Böni; A Wellmann; Y G Man; G Hofbauer; U Brinkmann
Journal:  Am J Dermatopathol       Date:  1999-04       Impact factor: 1.533

5.  Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.

Authors:  Véronique Ouellet; Marie-Claude Guyot; Cécile Le Page; Abdelali Filali-Mouhim; Christian Lussier; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson
Journal:  Int J Cancer       Date:  2006-08-01       Impact factor: 7.396

Review 6.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

Review 7.  ras oncogenes in human cancer: a review.

Authors:  J L Bos
Journal:  Cancer Res       Date:  1989-09-01       Impact factor: 12.701

Review 8.  Shedding microvesicles: artefacts no more.

Authors:  Emanuele Cocucci; Gabriella Racchetti; Jacopo Meldolesi
Journal:  Trends Cell Biol       Date:  2009-01-12       Impact factor: 20.808

Review 9.  Targeting vesicle trafficking: an important approach to cancer chemotherapy.

Authors:  Paul K Wright
Journal:  Recent Pat Anticancer Drug Discov       Date:  2008-06       Impact factor: 4.169

10.  Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers.

Authors:  Johan Skog; Tom Würdinger; Sjoerd van Rijn; Dimphna H Meijer; Laura Gainche; Miguel Sena-Esteves; William T Curry; Bob S Carter; Anna M Krichevsky; Xandra O Breakefield
Journal:  Nat Cell Biol       Date:  2008-11-16       Impact factor: 28.824

View more
  21 in total

1.  High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.

Authors:  Szu-Ying Chin; Pei-Ru Wu; Yi-Hsien Shih; Chung-Min Yeh; Woan-Ruoh Lee; Shing-Chuan Shen; Kun-Tu Yeh; Ming-Chung Jiang; Jonathan Te-Peng Tseng
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Cellular apoptosis susceptibility protein (CAS) suppresses the proliferation of breast cancer cells by upregulated cyp24a1.

Authors:  Mei Ye; Ruigang Han; Jianwu Shi; Xunda Wang; Allan Z Zhao; Fanghong Li; Hao Chen
Journal:  Med Oncol       Date:  2020-04-08       Impact factor: 3.064

Review 3.  CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy.

Authors:  Ming-Chung Jiang
Journal:  Tumour Biol       Date:  2016-09-05

Review 4.  Tumor-derived extracellular vesicles: Potential tool for cancer diagnosis, prognosis, and therapy.

Authors:  Tayyaba Saleem; Aleena Sumrin; Muhammad Bilal; Hamid Bashir; Muhammad Babar Khawar
Journal:  Saudi J Biol Sci       Date:  2022-01-12       Impact factor: 4.052

Review 5.  Microparticles: biogenesis, characteristics and intervention therapy for cancers in preclinical and clinical research.

Authors:  Yan Hu; Yajie Sun; Chao Wan; Xiaomeng Dai; Shuhui Wu; Pui-Chi Lo; Jing Huang; Jonathan F Lovell; Honglin Jin; Kunyu Yang
Journal:  J Nanobiotechnology       Date:  2022-04-13       Impact factor: 10.435

6.  Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.

Authors:  Woan-Ruoh Lee; Shing-Chuan Shen; Yi-Hsien Shih; Chia-Lun Chou; Jonathan Te-Peng Tseng; Szu-Ying Chin; Kao-Hui Liu; Yen-Chou Chen; Ming-Chung Jiang
Journal:  J Transl Med       Date:  2015-06-13       Impact factor: 5.531

Review 7.  Biology and biogenesis of shed microvesicles.

Authors:  Christopher Tricarico; James Clancy; Crislyn D'Souza-Schorey
Journal:  Small GTPases       Date:  2016-08-05

8.  Correlations between cytoplasmic CSE1L in neoplastic colorectal glands and depth of tumor penetration and cancer stage.

Authors:  Cheng-Jeng Tai; Tzu-Cheng Su; Ming-Chung Jiang; Hung-Chang Chen; Shing-Chuan Shen; Woan-Ruoh Lee; Ching-Fong Liao; Ying-Chun Chen; Shu-Hui Lin; Li-Tzu Li; Ko-Hung Shen; Chung-Min Yeh; Kun-Tu Yeh; Ching-Hsiao Lee; Hsin-Yi Shih; Chun-Chao Chang
Journal:  J Transl Med       Date:  2013-01-31       Impact factor: 5.531

9.  A Fraction of CD133+ CNE2 Cells Is Made of Giant Cancer Cells with Morphological Evidence of Asymmetric Mitosis.

Authors:  Qingping Jiang; Qianbing Zhang; Shuang Wang; Siming Xie; Weiyi Fang; Zhen Liu; Jinsong Liu; Kaitai Yao
Journal:  J Cancer       Date:  2015-10-20       Impact factor: 4.207

10.  A Novel Mutation in Cse1l Disrupts Brain and Eye Development with Specific Effects on Pax6 Expression.

Authors:  Lauren E Blizzard; Chelsea Menke; Shaili D Patel; Ronald R Waclaw; Salil A Lachke; Rolf W Stottmann
Journal:  J Dev Biol       Date:  2021-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.